Atlas Trials

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Clinical trial NCT02860559 · UNKNOWN

Trial details

NCT number
NCT02860559
Sponsor
Taiga Biotechnologies, Inc.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Severe Combined Immunodeficiency
Start date
2021-08-01
Primary completion
2024-02-01
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.